Patent Application Titled "Combination Of Micheliolide Derivatives Or Nanoparticles With Ionizing Radiation And Checkpoint Inhibitors For Cancer Therapy" Published Online (USPTO 20230036839).
In: Cancer Gene Therapy Week, 2023-02-20, S. 73-73
serialPeriodical
Zugriff:
For instance, there is an ongoing need for additional cancer treatment methods and compositions that can be used to treat drug- and/or radio-resistant cancers and/or that can be used to treat cancer while avoiding the development of drug- and/or radio-resistant cancer cells." In some embodiments, the immune checkpoint inhibitor is selected from the group comprising a PD-1 inhibitor, a PD-L1 inhibitor, a CTLA-4 inhibitor, an IDO inhibitor, a CCR7 inhibitor, an OX40 inhibitor, a TIM3 inhibitor, and a LAG3 inhibitor. [Extracted from the article]
Copyright of Cancer Gene Therapy Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Application Titled "Combination Of Micheliolide Derivatives Or Nanoparticles With Ionizing Radiation And Checkpoint Inhibitors For Cancer Therapy" Published Online (USPTO 20230036839).
|
---|---|
Zeitschrift: | Cancer Gene Therapy Week, 2023-02-20, S. 73-73 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6837 (print) |
Schlagwort: |
|
Sonstiges: |
|